secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001437749-26-001543
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma launches EXXUA for MDD; reports $32.6M cash, reduced launch budget to $6-8M
--------------------------------------------------------------------------------

- EXXUA (gepirone) is first FDA-approved 5HT1a agonist for MDD; full commercial launch underway after Dec 15, 2025 initial availability.
- Cash $32.6M as of 9/30/25; TTM adjusted EBITDA $6.7M; launch budget reduced from $10M to $6-8M.
- Commercialization deal with Fabre-Kramer: $3M upfront, 28% base royalty plus 3% on COGS, milestones starting at $100M net sales.
- Pivotal trials showed significant HAM-D17 improvement vs placebo (P=0.018 and P=0.032); no sexual dysfunction or weight gain warning.
- Targeting 5,500 high-value psychiatry prescribers; 40+ person sales force; virtual team to deliver 20,000 contacts in launch phase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774926001543/0001437749-26-001543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774926001543/aytu20260118_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-001543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer